ArticleMolecular and cellular biochemistry2008
Transformation and actions of extracellular NADP(+) in the rat liver.
Article in Molecular and cellular biochemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Depletion of NADP(H) due to CD38 activation triggers endothelial dysfunction in the postischemic heart.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The possible actions and transformation of extracellular NADP(+) in the rat liver have not yet been studied. Considering the various effects of its analogue NAD(+) in the liver, however, effects of NADP(+) can equally be expected. In the present work, this question was approached in the isolated perfused rat liver to get a preliminary picture of the action of extracellular NADP(+) in this organ. NADP(+) (100 microM) produced transient increases in the portal perfusion pressure. Glucose release (glycogenolysis) and lactate production from endogenous glycogen were transiently increased in antegrade and retrograde perfusion. Oxygen uptake was stimulated after a transient inhibition in antegrade perfusion, which was practically absent in retrograde perfusion. Pyruvate production was transiently inhibited. In the absence of Ca(2+), all of these effects were no longer observed. Bromophenacyl bromide, an inhibitor of eicosanoid synthesis, almost abolished all effects. Suramin, a non-specific purinergic P2(YX) antagonist, also inhibited the action of NADP(+). Single pass transformation of 75 microM NADP(+) was equal to 92%. Besides nicotinamide, at least two additional transformation products were detected: 2'-phospho-ADP-ribose and a non-identified component, the former being more important (67% of the transformed NADP(+)). Nicotinic acid adenine dinucleotide phosphate (NAADP) was not found in the outflowing perfusate. It was concluded that NADP(+), like NAD(+), acts on perfusion pressure and glycogen catabolism in the liver mainly via eicosanoid synthesis mediated by purinergic P2(YX) receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.